**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript No: 9537**

**Columns: Prospective Study**

***Apolipoprotein C3* (−455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the southern Han Chinese population**

Li MR *et al. Apolipoprotein C3* polymorphism in NAFLD

Min-rui Li, Sheng-hong Zhang, Kang Chao, Xian-hua Liao, Jia-yan Yao, Min-hu Chen, Bi-hui Zhong

**Minrui Li, Sheng-hong Zhang, Kang Chao, Xian-hua Liao, Jia-yan Yao, Minhu Chen, Bi-hui Zhong,** Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China

**Author contributions:** LiMRand Zhang SH contributed equally to this work; Li MR and Zhang SH designed the research; Li MR, Chao K, Liao XH and Yao JY performed the research; Li MR and Zhang SH contributed to the statistical analyses and wrote the paper; Zhong BH and Chen MH revised the paper.

**supported by** Natural Scientific Foundation of Guangdong Province, No. S2012040007685; Doctoral Program Foundation of Institutions of Higher Education of China, No. 20120171120090; and National Natural Science Foundation of China, No. 81301769 and No. 81170392

**Correspondence to: Bi-hui Zhong, MD, PhD****,** Division of Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58 Zhongshan Road II, Guangzhou 510080, Guangdong Province, China. sophiazhong@medmail.com.cn

**Telephone:** +86-20-87755766 **Fax:** +86-20-87332916

**Received:** February 26, 2014 **Revised:** April 18, 2014

**Accepted:** May 29, 2014

**Published online:**

**Abstract**

**aim:** to investigate the relationship between *ApolipoproteinC3* (*APOC3*) (–455T>C) polymorphism and nonalcoholic fatty liver disease (NAFLD) in the Southern Chinese Han population.

**Methods:** In this prospective case-control study, we recruited 300 NAFLD patients and 300 healthy controls to a cohort representing Southern Chinese Han population at The First Affiliated Hospital, Sun Yat-sen University, from January to December 2012. Polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing were used to genotype the *APOC3* (−455T>C) variants.

**Results:** After adjusting for age, gender, and body-mass index, TC and CC genotypes were found to increase the susceptibility to NAFLD compared to that of the TT genotype, with adjusted odds ratios (ORs) of 1.77 (95%CI: 1.16−2.72) and 2.80 (95%CI: 1.64−4.79), respectively. Further stratification analysis indicated that the CC genotype was more susceptible to insulin resistance (IR) than the TT genotype, with OR of 3.24 (95%CI: 1.52−6.92). The CC genotype also was associated with a much higher risk of hypertension, hypertriglyceridemia, and low levels of high-density lipoprotein cholesterol (HDL) (*P <* 0.05). No association was found between the *APOC3* (−455T>C) polymorphism and obesity, impaired glucose tolerance, hyperuricemia, hypercholesterolemia, and high levels of low-density lipoprotein cholesterol (LDL) (*P >* 0.05).

**Conclusion:** *APOC3* (−455T>C) genetic variation is involved in the susceptibility to developing NAFLD, IR, hypertension, hypertriglyceridemia, and low HDL in the Southern Chinese Han population.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** *ApolipoproteinC3*; Nonalcoholic fatty liver disease; Insulin resistance; Metabolic disorder; Polymorphism

**Core tip:** This study represents the first study to investigate the relationship between the *ApolipoproteinC3* (*APOC3*) (–455T>C) polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility in the Southern Chinese Han population. After adjusting for age, gender, and body-mass index, we found that *APOC3* (−455T>C) genetic variation was involved in the susceptibility to developing NAFLD, insulin resistance, hypertension, hypertriglyceridemia, and low high-density lipoprotein cholesterol. In the additive genetic model, variant-type homozygote CC showed the highest susceptibility to the above disorders, followed by heterozygote TC and wild-type homozygote TT, respectively.

Li MR, Zhang SH, Chao K, Liao XL, Yao YJ, Chen MH, Zhong BH. *Apolipoprotein C3* (−455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the southern Han Chinese population. *World J Gastroenterol* 2014; In press

**Introduction**

Nonalcoholic fatty liver disease (NAFLD) is an escalating public health problem, affecting up to 35% of adults in the United States and 15% in relatively affluent regions in China[1,2]. NAFLD includes a spectrum of hepatic disorders extending from nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), fibrosis/cirrhosis, and hepatocellular carcinoma (HCC). It was estimated that 10%−20% of patients with NAFL would develop NASH, and 10%−29% patients with NASH would progress to cirrhosis within 10 years[3,4]. The hallmark of NAFLD is an imbalance between triglyceride (TG) acquisition and removal in the liver, and steatosis is defined as TG accumulation to levels that are more than 5% of the total liver weight. Therefore, genetic factors that promote TG acquisition in the liver and inhibit TG removal from the liver would cause steatosis[5]. The major pathway for TG export from the liver is secretion into the blood as very-low-density lipoprotein (VLDL). Mutations in the major components involved in VLDL pathways may be additional causes for hepatic steatosis[5].

Apolipoprotein C3 (APOC3) is a major constituent of VLDL, and inhibits the hydrolysis of TG-rich particles by lipoprotein lipase[6]. Transgenic mice overexpressing human *APOC3* were predisposed to hepatic steatosis, which indicated that *APOC3* might play an important role in the development of NAFLD[7,8]. Recently, a single-nucleotide polymorphism [SNP; rs2854116, *APOC3* (−455T>C)] in the promoter region of *APOC3* has been reported to be associated with the susceptibility to develop NAFLD and insulin resistance (IR)[9]. However, conclusions drew from other studies were not in accordance with that[10-12]. This inconsistency might be due to factors such as gender, geographical region, and ethnicity. Until now, no data about this field has been reported in the Southern Chinese Han population. In this prospective case-control study, we explore the genotype frequency of *APOC3* (−455T>C) in the Southern Chinese Han population and analyze its association with NAFLD and metabolic disorders.

**MATERIALS AND METHODS**

***Ethics statement***

This study protocol was approved by the Human Ethics Committee of The First Affiliated Hospital, Sun Yat-sen University. In addition, written consent was given by the patients for their information to be stored in the hospital database and used for research.

***Subjects***

A prospective, case-control study enrolled 600 unrelated individuals, including 300 NAFLD patients and 300 age- and gender-matched healthy controls, between January and December 2012. The study was conducted in the health examination center of The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. The male-to-female ratio was 2. For the NAFLD group, subjects were enrolled after a diagnosis of fatty-liver defined by the presence of at least two of following three abnormal findings on abdominal ultrasonography: diffusely increased liver near field ultrasound echo (“bright liver”); liver echo greater than kidney; vascular blurring and the gradual attenuation of far field ultrasound echo[13]. Subjects with secondary diagnoses of hepatic steatosis, such as that caused by alcohol abuse (alcohol consumption > 140 g per week in men or > 70 g per week in women), hepatitis B, hepatitis C, or other cryptogenic liver diseases, were excluded from the study. For the healthy control group, subjects who were free of elevated alanine aminotranferase (ALT) or aspartate aminotransferase (AST) and have no liver steatosis examined by abdominal ultrasonography, and lacked any sign of metabolic disorders such as hypertension, overweight, obesity, hyperuricemia, and dyslipidemia were enrolled. All subjects were of Southern Chinese Han ethnicity.

***Clinical data collection***

Demographic and clinical data were collected by structured interview using aquestionnaire. Body mass, height, and blood pressure were measured by trained nurses. Body-mass index [BMI (kg/m2)] was calculated. BMI ≥ 25 kg/m2 was considered as obesity. Abdominal ultrasonography and blood biochemical analysis were routinely conducted. TG, high-density lipoprotein cholesterol (HDL), total cholesterol, low-density lipoprotein cholesterol (LDL), fasting plasma glucose (FPG), fasting plasma insulin (FPI), serum uric acid (UA), ALT, and AST were measured by Abbott i2000 Automatic Biochemistry Analyzer (Abbott, United States). The homeostasis model for assessment of insulin resistance (HOMA-IR) was calculated as described in previous study[14]. IR was defined as HOMA-IR > 3. Hypertension, low HDL, hypertriglyceridemia, and impaired glucose tolerance (IGT) were diagnosed using the International Diabetes Federation consensus worldwide definition of metabolic syndrome[15]. Hyperuricemia, hypercholesterolemia, and increased LDL were diagnosed according to American College of Rheumatology guidelines for management of gout and ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults[16,17].

***DNA extraction***

Genomic DNA was extracted from 200 ul of peripheral blood using the Blood DNA Extraction Kit (Qiagen, Germany). DNA concentration and quality were measured and assessed by Nanodrop 2000C (Thermo Fisher, United States) and 2% agarose gel electrophoresis (Sigma, Germany).

***Genotype analysis***

Genotypes of *APOC3* (−455T>C) were examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The primers were described previously[18], and were used for PCR with annealing temperature of 68 °C to amplify a 194-bp fragment containing the *APOC3* target site (−455T>C). PCR products were separated by 8% polyacrylamide gel electrophoresis (PAGE) after digesting with BtsCI (New England BioLabs, United States) at 50 °C water incubator overnight. To confirm the genotyping results, randomly selected PCR samples were examined by DNA sequencing using ABI 3730 XL (ABI, United States) with the chain termination method (Shenzhen BGI, China).

***Statistical analysis***

Data were analyzed using SPSS software (version 19.0, IBM, United States). Hardy-Weinberg equilibrium in the control group was tested using Pearson’s *χ*2-test. Logistic regression analyses were performed to obtain the odds ratio (OR) and their 95% confidence interval (CI). Age (> 40 years), gender, and BMI were considered as potential confounders for NAFLD and metabolic disorders including hypertension, IR, IGT, dyslipidemia, and hyperuricemia. Therefore, they were included in the multivariate analyses with forward conditional method when we explored the association between the *APOC3* (–455T>C) polymorphism and NAFLD susceptibility and the above metabolic disorders. Independent *t*-tests or nonparametric Mann–Whitney *U* tests were used as appropriate to evaluate the difference between the contol and NAFLD group. A two-tailed *P* < 0.05 was considered statistically significant.

**Results**

***Clinical characteristics***

There was no significant difference between the NAFLD group and the control group with respect to the age and gender distribution (Table 1). Measurement values of BMI, blood pressure, UA, FPG, FPI, and lipid profile were significantly different between controls group and NAFLD group (*P <* 0.001, Table 1). Obesity, elevated AST, low HDL, hypercholesterolemia, and hypertriglyceridemia were the most common characteristics in the NAFLD group (Table 1).

***APOC3 (−455T>C) polymorphism***

Genotypes of all 600 subjects including 300 NAFLD patients and 300 controls were successfully assessed by PCR-RFLP. The PCR-RFLP products separated into three genotypes, including wild-type homozygote (TT), heterozygote (TC), and variant-type homozygote (CC). These genotypes resolved as fragments of 122 and 72bp (TT); 122, 72, and 194bp (TC); and 194bp (CC) (Figure 1). These genotypes were confirmed by DNA sequencing in randomly selected samples (Figure 2). Among healthy controls, the *APOC3* genotype distribution was in Hardy-Weinberg equilibrium (*P >* 0.05).

***Association between the*** ***APOC3 (−455T>C) polymorphism and NAFLD susceptibility***

The frequencies of *APOC3* (−455T>C) genotypes in the control group (44.7% TT, 41.0% TC, and 14.3% CC) were significantly different from those in the NAFLD group (31.3% TT, 43.7% TC, and 25.0% CC) (*P <* 0.001) (Table 2). After adjusting for age, gender, and BMI, the TC and CC genotypes showed an increased risk of NAFLD, with adjusted ORs of 1.77 (95%CI: 1.16**−**2.72) and 2.80 (95%CI: 1.64**−**4.79), respectively (Table 2).

***Correlation of the APOC3 (−455T>C) polymorphism with IR or IGT in the NAFLD group***

Compared to that of the TT genotype, the CC genotype was associated with an increased risk of IR in NAFLD patients, with adjusted OR of 3.24 (95%CI: 1.52−6.92). The TC genotype shared the similar frequency in both non-IR and IR patients in NAFLD group (95%CI: 0.97−3.96, *P =* 0.06). In addition, no association was found between the *APOC3* (−455T>C) polymorphism and IGT in NAFLD group (*P >* 0.05) (Table 3).

***Correlation of the APOC3 (−455T>C) polymorphism with hypertension, or dyslipidemia in the NAFLD group***

Compared to that of the TT genotype, the TC and CC genotypes were associated with an increased risk of hypertension in NAFLD patients, with adjusted OR of 2.16 (95%CI: 1.02−4.57) and 3.42 (95%CI: 1.53−7.60), respectively (Table 4).

Compared to that of the TT genotype, NAFLD patients with the TC and CC genotypes were more susceptible to hypertriglyceridemia, with adjusted OR of 2.03 (95%CI: 1.12−3.68) and 3.80 (95%CI: 1.95−7.41), respectively. The CC genotype was associated with a much higher risk of low HDL in NAFLD patients, with adjusted OR of 2.34 (95%CI: 1.21−4.52) compared to that of the TT genotype. The TC genotype had a similar incidence of low HDL as that of the TT genotype (95%CI: 0.76−2.42, *P =* 0.30). No association between the *APOC3* (−455T>C) polymorphism and hypercholesterolemia or increased LDL was found in the Southern Chinese Han population (*P >* 0.05) (Table 4). No association was found between the *APOC* (–455T>C) polymorphism and obesity, hyperuricemia, elevated ALT and AST (*P >* 0.05, data not shown).

**Discussion**

The present study examined 300 NAFLD patients and 300 healthy controls to investigate the relationship between *APOC3* (−455T>C) polymorphism and NAFLD susceptibility in the Southern Chinese Han population. We found that variation in *APOC3* (−455T>C) conferred susceptibility to NAFLD. These results did not support those of previous studies from Shenyang and Qingdao (the Northern China) that found no association between *APOC3* (−455T>C) and susceptibility to NAFLD[19,20]. These inconsistencies may be explained by several considerations. First, the previous studies performed in Shenyang and Qingdao enrolled Northern Chinese population as the study subjects. By contrast, our study was performed in Southern China and enrolled only the Southern Chinese Han population. Secondly, the two previous studies defined healthy controls as “no hepatic steatosis.” This was different from our definition of healthy controls as “subjects who were free of elevated ALT or AST and have no liver steatosis, and lacked any kind of metabolic disorders such as hypertension, obesity, hyperuricemia, and dyslipidemia”. In fact, similar discrepancies were found in studies of the association between *APOC3* (−455T>C) polymorphism and acute coronary syndrome (ACS) that were conducted in different regions of China[21,22]. Thirdly, page gel was used to differentiate PCR products after enzyme digesting. This method had a much higher sensitivity in detecting PCR products with small size.

Our discovery of the association between *APOC3* (−455T>C) polymorphism and NAFLD was similar to the results from a study of an Asian Indian population[9], which revealed that C allel carriers showed markedly higher hepatic TG content (HTGC)[9]. By contrast, another study enrolling multi-ethnicities showed that the C allel carrier was associated with a significant reduction in HTGC in African Americans[10], while the association was not found in European American and Hispanics. Other two studies enrolling Finns and Caucasians didn’t find the association either[12,23].

There is strong evidence for a close association between NAFLD and IR[24-28]. IR is a key disorder that promotes the development and progression of NAFLD, and it is associated with *APOC3*[7,8,29,30]. Transgenic mice overexpressing human *APOC3* were predisposed to hepatic steatosis and IR[7,8]. In our study, NAFLD patients had a greater probability of IR than that of controls, as expected (24.7% *vs* 1.3%, *P <* 0.001). Subjects carrying the C allele (TC or CC) developed IR more easily, and it was in agreement with the Indian population[9]. However, one study recruiting multi-ethnicities including African American, European American and Hispanics found no association between *APOC3* (–455T>C) polymorphism and the level of HOMA-IR except in Hispanics. And C allel showed a lower level of HOMA-IR[10]. No association between *APOC3* (−455T>C) polymorphism and IGT was found in our study. These results might be due to the small sample size of NAFLD patients with IGT [67 of 300 (22.3%)].

The association between *APOC3* (−455T>C) polymorphism and metabolic syndrome (MetS) has been reported, in which an *APOC3* variant was associated with a greater likelihood of MetS compared with that of wild type[31-33]. Carriers of *APOC3* (−455T>C) variations were more susceptible to metabolic disorders, such as hypertriglyceridemia, low HDL levels[21,34], and hypertension[31]. However, no association between *APOC3* (−455T>C) and total cholesterol or LDL was found in our study or in a previous study[34]. The role of *APOC3* in lipid metabolism was confirmed in a study that showed a null mutation of *APOC3* lead to lower fasting and postprandial plasma TGs, higher levels of HDL, and lower levels of LDL[35].

The −455T>C conversion is located in a putative insulin-response element of *APOC3*, which is associated with plasma TG levels[33,36,37]. *In vitro* promoter studies indicated that insulin bound to this site and inhibited *APOC3* transcription and translation. By contrast, the polymorphic variants prevent insulin binding and promote *APOC3* transcription, thus promoting the synthesis of APOC3. As a result, the level of circulating APOC3 increases and acts as a lipoprotein lipase inhibitor, leading to decreased clearance of TG-rich particles, which ultimately results in hypertriglyceridemia[38,39]. The circulating TG-rich particles are preferentially taken up by the liver by means of a receptor-mediated process[40-42], which results in NAFLD and hepatic insulin resistance.

The reasons for the different conclusions between our study and previous studies are not clear[10,23,43]. One possible explanation might be that alcohol use, obesity, and exercise training confounded the relationship between *APOC3* (−455T>C) polymorphism, NAFLD susceptibility, and IR. Another possibility might be different roles of *APOC3* (−455T>C) polymorphism in different ethnicities. Previous studies examined *APOC3* polymorphisms in Asian Indian, African American, European American, Hispanic, Finnish, Caucasians, and Northern Chinese Han population[9-12,19,20] (Table 5), but the association between *APOC3* (−455T>C) polymorphism and NAFLD susceptibility was found only in the Asian Indian and African American population. We examined the Southern Chinese Han population to assess the correlation between *APOC3* (−455T>C) polymorphism and NAFLD susceptibility, and the result was similar to that of the Asian Indian population[9].

In summary, our results indicate that *APOC3* (−455T>C) polymorphism is associated with an increased susceptibility for NAFLD, IR, and metabolic disorders. However, there are several limitations in our study. First, the diagnosis of NAFLD was based primarily on ultrasonographic results, not on the quantitative measurement of hepatic TG content by magnetic resonance. Second, the serum concentration of APOC3 was not obtained in our study. Further studies will be conducted to explore the function of *APOC3* polymorphism.

***comments***

***Background***

The pathogenesis of nonalcoholic fatty liver disease (NAFLD) has not been elucidated clearly, but it was supposed to be closely related with genetic factors due to its high prevalence among first-degree relatives or twins. Recently, *ApolipoproteinC3* (*APOC3*) (−455T>C) genetic variation has been reported to be susceptible NAFLD and IR in Indian population. However, the conclusion drew from studies performed in African Americans, European Americans, Hispanics, Caucasians, and Finns were not in accordant with that of the Indian population. Until now, no data about the association between the *APOC3* (−455T>C) polymorphism and NAFLD in the Southern Chinese Han population were reported.

***Research frontiers***

The relationship between *APOC3* (−455T>C) and NAFLD varied in different ethnicities. Therefore, studies performed in the same procedures and methods enrolling more ethnicities were needed. In addition, further studies should be conducted to explore the function of *APOC3* (–455T>C) polymorphism.

***Innovations and breakthroughs***

This study represents the first published study to investigate the relationship between the *APOC3* (–455T>C) polymorphism and NAFLD susceptibility in the Southern Chinese Han population.

***Applications***

Physicians would pay more attention to individuals who were C allel carriers of *APOC3* (–455T>C), and provide early intervention before the NAFLD development.

***Peer review***

The association between APOC3(-455T>C) and NAFLD susceptibility in Han Chinese population is one of major interest. This manuscript is very interesting from this aspect.

**Reference**

1 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]

2 **Fan JG**, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. *J Hepatol* 2009; **50**: 204-210 [PMID: 19014878 DOI: 10.1016/j.jhep.2008.10]

3 **Neuschwander-Tetri BA**, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 2003; **37**: 1202-1219 [PMID: 12717402 DOI: 10.1053/jhep.2003.50193]

4 **Argo CK**, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis* 2009; **13**: 511-531 [PMID: 19818302 DOI: 10.1016/j.cld.2009.07.005]

5 **Cohen JC**, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. *Science* 2011; **332**: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]

6 **McConathy WJ**, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. *J Lipid Res* 1992; **33**: 995-1003 [PMID: 1431591]

7 **Ito Y**, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. *Science* 1990; **249**: 790-793 [PMID: 2167514]

8 **Lee HY**, Birkenfeld AL, Jornayvaz FR, Jurczak MJ, Kanda S, Popov V, Frederick DW, Zhang D, Guigni B, Bharadwaj KG, Choi CS, Goldberg IJ, Park JH, Petersen KF, Samuel VT, Shulman GI. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. *Hepatology* 2011; **54**: 1650-1660 [PMID: 21793029 DOI: 10.1002/]

9 **Petersen KF**, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. *N Engl J Med* 2010; **362**: 1082-1089 [PMID: 20335584 DOI: 10.1056/NEJMoa0907295]

10 **Kozlitina J**, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. *Hepatology* 2011; **53**: 467-474 [PMID: 21274868 DOI: 10.1002/Hep.24072]

11 **Sentinelli F**, Romeo S, Maglio C, Incani M, Burza MA, Scano F, Coccia F, Cossu E, Leonetti F, Baroni MG. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. *Lipids Health Dis* 2011; **10**: 93 [PMID: 21663607 DOI: 10.1186/1476-511X-10-93]

12 **Hyysalo J**, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, Lundbom N, Rissanen A, Krauss RM, Melander O, Orho-Melander M, Yki-Järvinen H. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2012; **27**: 951-956 [PMID: 22141340 DOI: 10.1111/j.1440-1746.2011.07045.x]

13 **Fan JG**, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 163-166). *J Dig Dis* 2011; **12**: 38-44 [PMID: 21276207 DOI: 10.1111/j.1751-2980.2010]

14 **Bonora E**, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. *Diabetes Care* 2000; **23**: 57-63 [PMID: 10857969]

15 **Alberti KG**, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006; **23**: 469-480 [PMID: 16681555 DOI: 10.1111/j.1464-5491]

16 **Khanna D**, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* (Hoboken) 2012; **64**: 1431-1446 [PMID: 23024028 DOI: 10.1002/acr.21772]

17 **Greenland P**, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; **56**: e50-103 [PMID: 21144964 DOI: 10.1016/j.jacc.2010]

18 **Dallongeville J**, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N. Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. *Atherosclerosis* 2000; **150**: 149-157 [PMID: 10781646]

19 **Li Y**, Xing C, Cohen JC, Hobbs HH. Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. *Hepatology* 2012; **55**: 327-328 [PMID: 21898508 DOI: 10.1002/hep.24659]

20 **Niu TH**, Jiang M, Xin YN, Jiang XJ, Lin ZH, Xuan SY. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. *World J Gastroenterol* 2014; **20**: 3655-3662 [PMID: 24707151 DOI: 10.3748/wjg.v20.i13.3655]

21 **Ding Y**, Zhu MA, Wang ZX, Zhu J, Feng JB, Li DS. Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. *J Biomed Biotechnol* 2012; **2012**: 509420 [PMID: 22675253 DOI: 10.1155/2012/509420]

22 **Yu J**, Huang J, Liang Y, Qin B, He S, Xiao J, Wang H, Zhong R. Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China. *Lipids Health Dis* 2011; **10**: 200 [PMID: 22054125 DOI: 10.1186/1476-511X-10-200]

23 **Lallukka S**, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. *Diabetologia* 2013; **56**: 886-892 [PMID: 23334462 DOI: 10.1007/s00125-013-]

24 **Petersen KF**, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. *J Clin Invest* 2002; **109**: 1345-1350 [PMID: 12021250 DOI: 10.1172/JCI15001]

25 **Seppälä-Lindroos A**, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *J Clin Endocrinol Metab* 2002; **87**: 3023-3028 [PMID: 12107194 DOI: 10.1210/jcem.87.7.8638]

26 **Petersen KF**, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005; **54**: 603-608 [PMID: 15734833]

27 **Samuel VT**, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J Biol Chem* 2004; **279**: 32345-32353 [PMID: 15166226 DOI: 10.1074/jbc.M313478200]

28 **Samuel VT**, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. *J Clin Invest* 2007; **117**: 739-745 [PMID: 17318260 DOI: 10.1172/JCI30400]

29 **Duivenvoorden I**, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. *Diabetes* 2005; **54**: 664-671 [PMID: 15734841]

30 **Gariani K**, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. *Diabetes Metab* 2013; **39**: 16-26 [PMID: 23266468 DOI: 10.1016/j.diabet.2012.11.002]

31 **Pollex RL**, Ban MR, Young TK, Bjerregaard P, Anand SS, Yusuf S, Zinman B, Harris SB, Hanley AJ, Connelly PW, Huff MW, Hegele RA. Association between the -455T& gt; C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample. *BMC Med Genet* 2007; **8**: 80 [PMID: 18096054 DOI: 10.1186/1471-2350-8-80]

32 **Miller M**, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, Dwivedi M, Misra A. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. *Arch Med Res* 2007; **38**: 444-451 [PMID: 17416293 DOI: 10.1016/j.arcmed.2006.10.013]

33 **Guettier JM**, Georgopoulos A, Tsai MY, Radha V, Shanthirani S, Deepa R, Gross M, Rao G, Mohan V. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a South Indian population. *J Clin Endocrinol Metab* 2005; **90**: 1705-1711 [PMID: 15598690 DOI: 10.1210/jc.2004-1338]

34 **Likanonsakul S**, Rattanatham T, Feangvad S, Uttayamakul S, Prasithsirikul W, Srisopha S, Nitiyanontakij R, Tengtrakulcharoen P, Tarkowski M, Riva A, Nakayama EE, Shioda T. Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. *AIDS Res Hum Retroviruses* 2013; **29**: 142-150 [PMID: 22775001 DOI: 10.1089/AID.2012.0114]

35 **Pollin TI**, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. *Science* 2008; **322**: 1702-1705 [PMID: 19074352 DOI: 10.1126/science.1161524]

36 **Dammerman M**, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. *Proc Natl Acad Sci USA* 1993; **90**: 4562-4566 [PMID: 8099442]

37 **Waterworth DM**, Talmud PJ, Humphries SE, Wicks PD, Sagnella GA, Strazzullo P, Alberti KG, Cook DG, Cappuccio FP. Variable effects of the APOC3-482C & gt; T variant on insulin, glucose and triglyceride concentrations in different ethnic groups. *Diabetologia* 2001; **44**: 245-248 [PMID: 11270684 DOI: 10.1007/s001250051607]

38 **Li WW**, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. *J Clin Invest* 1995; **96**: 2601-2605 [PMID: 8675624 DOI: 10.1172/JCI118324]

39 **Jong MC**, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. *Arterioscler Thromb Vasc Biol* 1999; **19**: 472-484 [PMID: 10073946]

40 **Cooper AD**. Role of the liver in the degradation of lipoproteins. *Gastroenterology* 1985; **88**: 192-205 [PMID: 2981081]

41 **Windler EE**, Greeve J, Daerr WH, Greten H. Binding of rat chylomicrons and their remnants to the hepatic low-density-lipoprotein receptor and its role in remnant removal. *Biochem J* 1988; **252**: 553-561 [PMID: 3415673]

42 **Sherrill BC**, Dietschy JM. Characterization of the sinusoidal transport process responsible for uptake of chylomicrons by the liver. *J Biol Chem* 1978; **253**: 1859-1867 [PMID: 632244]

43 **Sookoian S**, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 2011; **53**: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]

**P-Reviewer:** Nakajima A **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Clinical characteristics between the control group and the nonalcoholic fatty liver disease group *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Items | Control | NAFLD | *P-*value | Frequencies of  disorders in NAFLD group |
| Gender (*n*) |  |  |  | -- |
| Male | 200 | 200 | 1.0 | -- |
| Female | 100 | 100 | -- |
| Age (yr) | 39.5 ± 9.1 | 40.7 ± 9.7 | 0.11 | -- |
| BMI(kg/m2) | 22.1 ± 2.8 | 26.3 ± 4.2 | < 0.001 | 186 (62.0) |
| Blood Pressure (mmHg) | -- | -- | -- | 64 (21.3) |
| Systolic pressure | 119 ± 13 | 127 ± 13 | < 0.001 | -- |
| Diastolic pressure | 75 ± 10 | 82 ± 9 | < 0.001 | -- |
| HDL (mmol/L) | -- | -- | -- | 128 (42.7) |
| Male | 1.4 ± 0.2 | 1.1 ± 0.2 | < 0.001 | 107 (53.5) |
| Female | 1.4 ± 0.2 | 1.3 ± 0.3 | < 0.001 | 21 (21.0) |
| Total cholesterol (mmol/L) | 4.7 ± 0.5 | 5.4 ± 1.0 | < 0.001 | 122 (40.7) |
| TG (mmol/L) | 1.0 ± 0.5 | 2.5 ± 2.5 | < 0.001 | 119 (39.7) |
| UA(umol/L) | -- | -- | -- | 104 (34.7) |
| Male | 335.3 ± 51.2 | 415.5 ± 97.2 | < 0.001 | 89 (44.5) |
| Female | 241.3 ± 39.5 | 324.0 ± 83.6 | < 0.001 | 15 (15.0) |
| LDL(mmol/L) | 2.7 ± 0.5 | 3.3 ± 0.9 | < 0.001 | 90 (30.0) |
| FPI (uU/mL) | 6.0 ± 3.1 | 10.62 ± 4.5 | < 0.001 | -- |
| HOMA-IR | 1.2 ± 0.7 | 2.4 ± 1.2 | < 0.001 | 74 (24.7) |
| FPG (mmol/L) | 4.8 ± 0.5 | 5.3 ± 1.1 | < 0.001 | 67 (22.3) |
| ALT (U/L) | 19.0 ± 8.7 | 42.1 ± 32.6 | < 0.001 | 114 (38.0) |
| AST (U/L) | 24.1 ± 4.9 | 33.1 ± 14.8 | < 0.001 | 148 (49.3) |

NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; HDL: High-density lipoprotein cholesterol; TG: Triglyceride; UA: Uric acid; LDL: Low-density lipoprotein cholesterol; FPI: Fasting plasma insulin; HOMA-IR: Homeostasis model of assessment for insulin resistance index; FPG: Fasting plasma glucose; ALT: Alanine aminotranferase; AST: Aspartate aminotransferase.

**Table 2 Association between *ApolipoproteinC3*** **(–455T>C) polymorphism and nonalcoholic fatty liver disease susceptibility *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Genotype** | **Groups** | | ***P-*value** | **Adjusted OR (95%CI)** |
|  | **Control group** | **NAFLD group** |  |  |
| TT | 134 (44.7) | 94 (31.3) | -- | 1 |
| TC | 123 (41.0) | 131 (43.7) | 0.0091 | 1.77 (1.16−2.72)1 |
| CC | 43 (14.3) | 75 (25.0) | < 0.0012 | 2.80 (1.64−4.79)2 |

1TC *vs* TT; 2CC *vs* TT. NAFLD: Nonalcoholic fatty liver disease.

**Table 3 Correlation between *ApolipoproteinC3* (–455T>C) polymorphism and insulin resistance, impaired glucose tolerance in the nonalcoholic fatty liver disease group *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Genotype** | **Metabolic components** | | ***P-*value** | **Adjusted OR (95%CI)** |
|  | **Non-IR** | **IR** |  |  |
| TT | 78 (34.5) | 16 (21.7) | -- | 1 |
| TC | 99(43.8) | 32 (43.2) | 0.061 | 1.96(0.97−3.96)1 |
| CC | 49 (21.7) | 26 (35.1) | 0.0022 | 3.24(1.52−6.92)2 |
|  | **Non-IGT** | **IGT** |  |  |
| TT | 77 (33.0) | 17 (25.4) | -- | 1 |
| TC | 98 (42.1) | 33 (49.2) | 0.231 | -- |
| CC | 58 (24.9) | 17 (25.4) | 0.892 | -- |

1TC *vs* TT; 2CC *vs* TT. IR: Insulin resistance; IGT: Impaired glucose tolerance.

**Table 4 Correlation between *ApolipoproteinC3* (–455T>C) polymorphism and hypertension, dyslipidemia in the nonalcoholic fatty liver disease group *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Genotype** | **Metabolic Components** | | ***P-*value** | **Adjusted OR (95%CI)** |
| **Non-hypertension** | **Hypertension** |
| TT | 82 (34.7) | 12(18.8) | - | 1 |
| TC | 102 (43.2) | 29(45.3) | 0.0431 | 2.16 (1.02−4.57)1 |
| CC | 52 (22.1) | 23(35.9) | 0.0032 | 3.42 (1.53−7.60)2 |
|  | **Non-hypertriglyceridemia** | **Hypertriglyceridemia** |  |  |
| TT | 71 (39.3) | 23 (19.3) | - | 1 |
| TC | 77 (42.5) | 54 (45.4) | 0.021 | 2.03 (1.12−3.68)1 |
| CC | 33 (18.2) | 42 (35.3) | < 0.0012 | 3.80 (1.95−7.41)2 |
|  | **Normal HDL** | **Low HDL** |  |  |
| TT | 63 (36.6) | 31 (24.2) | - | 1 |
| TC | 75 (43.6) | 56 (43.8) | 0.301 | 1.36 (0.76 −2.42)1 |
| CC | 34 (19.8) | 41 (32.0) | 0.012 | 2.34 (1.21 −4.52)2 |
|  | **Non-hypercholesterolemia** | **Hypercholesterolemia** |  |  |
| TT | 57 (32.0) | 37 (30.3) | - | 1 |
| TC | 81 (45.5) | 50 (41.0) | 0.521 | -- |
| CC | 40 (22.5) | 35 (28.7) | 0.202 | -- |
|  | **Normal LDL** | **Increased LDL** |  |  |
| TT | 65 (31.0) | 29 (32.2) | - | 1 |
| TC | 89 (42.3) | 42 (46.7) | 0.411 | -- |
| CC | 56 (26.7) | 19 (21.1) | 0.332 | -- |

1TC *vs* TT; 2CC *vs* TT. HDL: High-density lipoprotein cholesterol; LDL: Low-density lipoprotein cholesterol.

**Table 5 *ApolipoproteinC3* (–455T>C) polymorphism of different ethnics: data from the literature *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ethnicities** | **Genotypes of** ***APOC3* (-455T>C)** | | | **Ref.** |
| **TT** | **TC** | **CC** |
| African United States | 106 (8.7) | 484 (39.9) | 623 (51.4) | Kozlitina *et al*[10] |
| European | 316 (38.4) | 390 (47.4) | 117 (14.2) | Kozlitina *et al*[10] |
| Hipanics | 163 (37.7) | 209 (48.4) | 60 (13.9) | Kozlitina *et al*[10] |
| Finn | 145 (33.7) | 190 (44.2) | 95 (22.1) | Hyysalo *et al*[12] |
| Northern Chinese | 206 (25.8) | 375 (46.9) | 218 (27.3) | Niu *et al*[20] |

****

**Figure 1 Genotyping of *ApolipoproteinC3* (−455T>C) polymorphisms.** Polymerase chain reaction-restriction fragment length polymorphism polyacrylamide gel (8%) electrophoresis of the *ApolipoproteinC3* (−455T>C) polymorphisms illustrated the wild-type homozygote TT (122 and 72bp), heterozygote TC (194, 122, and 72bp), and variant-type homozygote CC (194bp) genotypes. TT: 4, 6-9; TC: 2, 3, 5; CC: 1.



**Figure 2 Sequencing analysis for genotypes of *ApolipoproteinC3* (−455T>C) polymorphisms.** A: TT genotype; B: TC genotype; C: CC genotype.